GSK_ Annual_Report_2021-22

41 the timelines laid down by the MCA. Unpaid/unclaimed dividend for seven years or more has also been transferred to the IEPF pursuant to the requirements under the Act. 13. Compliance with Secretarial Standards The Board of Directors affirms that the Company has complied with the applicable Secretarial Standards issued by the Institute of Company Secretaries of India (SS1 and SS2) respectively relating to Meetings of the Board and its Committees which have mandatory application. 14. General The information on conservation of energy, technology absorption and foreign exchange earnings and outgo as stipulated in section 134(3) M of the Companies Act, 2013, and the rules framed there under is attached herewith as Annexure ‘E’ which forms a part of this Report. The Disclosures pertaining to the remuneration and other details as required under section 197(12) of the Companies Act, 2013 and the rules made thereunder is enclosed as Annexure ‘F’ which forms a part of this Report. Pursuant to section 129(3) of the Companies Act, 2013, a statement in form ‘AOC-1’ containing salient features of the Financial Statements of the Subsidiary Company is attached. Pursuant to section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014, a statement in form ‘AOC-2’ relating to material contracts or arrangement or transactions at arm’s length basis of Company is attached. Although the audited statements of accounts, relating to Company’s subsidiary is no longer required to be attached to the Company’s Annual Report, the same is enclosed as and in way of better disclosure practice. The information relating to top ten employees in terms of remuneration and employees who were in receipt of remuneration of not less than ` 1.02 crores during the year or ` 8.5 lakhs per month during any part of the year forms part of this report and will be provided to any Member on a written request to the Company Secretary. In terms of Section 136 of the Act, the said report will be available for inspection of the Members through electronic mode up to the date of Annual General Meeting. The Members may write an email to in.investorquery@gsk.com by mentioning “Request for Inspection” in the subject of the email. 15. Acknowledgments The Directors expressed their appreciation for the contribution made by the employees to the significant improvement in the operations of the Company and for the support received from all other stakeholders, including members, doctors, medical professionals, customers, suppliers, business partners, and the government. The Board and the Management of your Company are indeed appreciative of the substantial support being received from GSK plc, the parent organization, in providing new healthcare solutions which are products of its discovery labs and the technology improvements which benefits your Company immensely. On behalf of the Board of Directors Ms. R. S. Karnad Mumbai, 16 May 2022 Chairperson